<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03869333</url>
  </required_header>
  <id_info>
    <org_study_id>CVIA 064</org_study_id>
    <nct_id>NCT03869333</nct_id>
  </id_info>
  <brief_title>Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]</brief_title>
  <official_title>A Phase 1 Double-blind, Placebo-controlled, Dose Escalating Study of Intramuscular Detoxified Shigella Flexneri 2a Artificial Invasin Complex (Invaplex[AR-DETOX]) Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of a Shigella flexneri 2a detoxified&#xD;
      artificial invasin complex (Invaplex[AR-Detox]) vaccine candidate administered by&#xD;
      intramuscular immunization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, Phase 1 clinical trial in which a&#xD;
      total of 60 volunteers will receive one of three doses of Invaplex[AR-DETOX] or placebo&#xD;
      (saline). The vaccine will be administered via intramuscular (IM) injection on study days 1,&#xD;
      22, and 43. Each participant will receive the same formulation at each vaccination dependent&#xD;
      upon group assignment. The study will be initiated with the lowest dose level (2.5 μg) and&#xD;
      will proceed to the next highest dose in an escalating fashion. All safety data will be&#xD;
      summarized and reviewed by the Protocol Safety Review Team (PSRT) prior to dose-escalation.&#xD;
&#xD;
      Specimens will be collected at prescribed intervals to examine systemic and mucosal immune&#xD;
      responses. Vaccine safety will be actively monitored during vaccination and for 28 days&#xD;
      following the third vaccine dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">June 12, 2020</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From first dose up to 28 days following the third immunization (71 days)</time_frame>
    <description>All adverse events (AEs) were assessed for severity by the investigator according to the following scale:&#xD;
Grade 1 (Mild): Does not interfere with routine activities, minimal level of discomfort;&#xD;
Grade 2 (Moderate): Interferes with routine activities, moderate level of discomfort;&#xD;
Grade 3 (Severe): Unable to perform routine activities, significant level of discomfort;&#xD;
Grade 4 (Potentially life-threatening): Hospitalization or ER visit for potentially life-threatening event.&#xD;
An AE was considered &quot;serious&quot; if it resulted in any of the following outcomes:&#xD;
Death&#xD;
Life-threatening AE&#xD;
Inpatient hospitalization or prolongation of existing hospitalization&#xD;
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions&#xD;
Congenital anomaly/birth defect.&#xD;
The Investigator assessed the relationship of each adverse event to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 1</measure>
    <time_frame>7 days after the first immunization (Days 1 to 7)</time_frame>
    <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 2</measure>
    <time_frame>7 days after the second immunization (Days 22 to 28)</time_frame>
    <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Events After Dose 3</measure>
    <time_frame>7 days after the third immunization (Days 43 to 49)</time_frame>
    <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events After Each Dose</measure>
    <time_frame>Dose 1: Days 1 to 21; Dose 2: Days 22 to 42; Dose 3: Days 43 to 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum Immunoglobulin A (IgA) Antibodies to Invaplex</measure>
    <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Serum Immunoglobulin G (IgG) Antibodies to Invaplex</measure>
    <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Immunoglobulin A Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant (ALS)</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Immunoglobulin G Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 4-fold Increase in Serum IgA Antibodies From Baseline</measure>
    <time_frame>Days 1 (Baseline), 22 43, 50, 57 and 71</time_frame>
    <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 4-fold Increase in Serum IgG Antibodies From Baseline</measure>
    <time_frame>Days 1 (Baseline), 22 43, 50, 57 and 71</time_frame>
    <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 4-fold Increase in ALS IgA From Baseline</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
    <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥ 4-fold Increase in ALS IgG From Baseline</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
    <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-rise (GMFR) in Serum IgA From Baseline</measure>
    <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-rise in Serum IgG From Baseline</measure>
    <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-rise in ALS IgA From Baseline</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-rise in ALS IgG From Baseline</measure>
    <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Invaplex[AR-Detox] 2.5 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invaplex[AR-Detox] 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invaplex[AR-Detox] 25 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Invaplex[AR-DETOX]</intervention_name>
    <description>Detoxified Shigella flexneri 2a Artificial Invasin Complex (Invaplex[AR-Detox]) Vaccine</description>
    <arm_group_label>Invaplex[AR-Detox] 10 μg</arm_group_label>
    <arm_group_label>Invaplex[AR-Detox] 2.5 μg</arm_group_label>
    <arm_group_label>Invaplex[AR-Detox] 25 μg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, male or female, age 18 to 50 years (inclusive) at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Completion and review of comprehension test (achieved ≥ 70% accuracy, two attempts&#xD;
             allowed).&#xD;
&#xD;
          -  Provide written informed consent before initiation of any study procedures.&#xD;
&#xD;
          -  Agrees to complete all study visits and procedures and to provide a screening stool&#xD;
             sample.&#xD;
&#xD;
          -  Women of childbearing capacity: Negative pregnancy test with understanding (through&#xD;
             informed consent process) to not become pregnant during the study or within three (3)&#xD;
             months following the last vaccine dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Health problems (for example, chronic medical conditions such as psychiatric&#xD;
             conditions, diabetes mellitus, hypertension, or any other conditions that might place&#xD;
             the subjects at increased risk of adverse events) - study clinicians, in consultation&#xD;
             with the Principal Investigator (PI), will use clinical judgment on a case-by-case&#xD;
             basis to assess safety risks under this criterion. The PI will consult with the&#xD;
             Research Monitor as appropriate.&#xD;
&#xD;
          -  History of autoimmune disorders, cardiovascular and renal disease.&#xD;
&#xD;
          -  Use of immunosuppressive medications (systemic corticosteroids or chemotherapeutics&#xD;
             that may influence antibody development), or immunosuppressive illness, including&#xD;
             immunoglobulin A (IgA) deficiency (defined by serum IgA &lt; 7 mg/dL).&#xD;
&#xD;
          -  Women who are pregnant or planning to become pregnant during the study period plus 3&#xD;
             months beyond the last vaccine dose and currently nursing women.&#xD;
&#xD;
          -  Participation in research involving another investigational product (defined as&#xD;
             receipt of an investigational product or exposure to an invasive investigational&#xD;
             device) 30 days before planned date of first vaccination or anytime throughout the&#xD;
             duration of the study until the last in-clinic study safety visit.&#xD;
&#xD;
          -  Positive blood test for hepatitis B surface antigen (HBsAG), hepatitis C virus&#xD;
             antibody (HCV Ab), human immunodeficiency virus (HIV)-1/HIV-2 antibody.&#xD;
&#xD;
          -  Clinically significant abnormalities on basic laboratory screening tests.&#xD;
&#xD;
          -  Systemic antimicrobial treatment (i.e., topical treatments are not an exclusion)&#xD;
             within 1 week before administration of the first vaccine dose.&#xD;
&#xD;
          -  Allergies that may increase the risk of adverse events (AEs).&#xD;
&#xD;
          -  Regular use (weekly or more often) of antidiarrheal, anti-constipation, or antacid&#xD;
             therapy.&#xD;
&#xD;
          -  Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on&#xD;
             a regular basis; loose or liquid stools on other than an occasional basis.&#xD;
&#xD;
          -  Personal or family history of an inflammatory arthritis.&#xD;
&#xD;
          -  Positive blood test for human leukocyte antigen (HLA) B27 (associated with increased&#xD;
             risk of reactive arthritis secondary to Shigella infection)&#xD;
&#xD;
          -  History of allergy to any vaccine.&#xD;
&#xD;
          -  Exclusionary skin disease history/findings that would confound assessment or prevent&#xD;
             appropriate local monitoring of AEs, or possibly increase the risk of a local AE.&#xD;
&#xD;
          -  Serum immunoglobulin G (IgG) titer &gt; 2500 to Shigella flexneri 2a lipopolysaccharide&#xD;
             antigen (LPS).&#xD;
&#xD;
          -  History of microbiologically confirmed Shigella infection.&#xD;
&#xD;
          -  Received previous licensed or experimental Shigella vaccine or live Shigella&#xD;
             challenge.&#xD;
&#xD;
          -  Travel to countries where Shigella or other enteric infections are endemic (most of&#xD;
             the developing world) within two years prior to dosing (clinician judgement).&#xD;
&#xD;
          -  Occupation involving handling of Shigella bacteria currently, or in the past 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramiro Gutierrez, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naval Medical Research Center (NMRC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research Clinical Trials Center (WRAIR CTC)</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <results_first_submitted>July 7, 2021</results_first_submitted>
  <results_first_submitted_qc>July 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shigella flexneri 2a</keyword>
  <keyword>Enteric</keyword>
  <keyword>Shigella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03869333/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03869333/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at the Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center (CTC) in Silver Spring, MD, USA. Healthy adults were recruited from the Baltimore/Washington, DC area.</recruitment_details>
      <pre_assignment_details>In this dose-escalation study participants were assigned to receive 3 vaccinations of 1 of 3 doses of detoxified Shigella flexneri 2a artificial invasin complex (Invaplex[AR-Detox]) or placebo. The study was initiated with the lowest dose level (2.5 μg) and proceeded to the next highest dose in an escalating fashion after review of safety data by the Protocol Safety Review Team.&#xD;
Within each dose cohort participants were randomly assigned to receive Invaplex[AR-Detox] or placebo in a 4: 1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Invaplex[AR-Detox] 2.5 μg</title>
          <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="P2">
          <title>Invaplex[AR-Detox] 10 μg</title>
          <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="P3">
          <title>Invaplex[AR-Detox] 25 μg</title>
          <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received First Dose</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Dose</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Third Dose</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled and randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Invaplex[AR-Detox] 2.5 μg</title>
          <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="B2">
          <title>Invaplex[AR-Detox] 10 μg</title>
          <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="B3">
          <title>Invaplex[AR-Detox] 25 μg</title>
          <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="9.4"/>
                    <measurement group_id="B2" value="33.6" spread="5.4"/>
                    <measurement group_id="B3" value="33.2" spread="7.1"/>
                    <measurement group_id="B4" value="28.9" spread="6.0"/>
                    <measurement group_id="B5" value="32.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>All adverse events (AEs) were assessed for severity by the investigator according to the following scale:&#xD;
Grade 1 (Mild): Does not interfere with routine activities, minimal level of discomfort;&#xD;
Grade 2 (Moderate): Interferes with routine activities, moderate level of discomfort;&#xD;
Grade 3 (Severe): Unable to perform routine activities, significant level of discomfort;&#xD;
Grade 4 (Potentially life-threatening): Hospitalization or ER visit for potentially life-threatening event.&#xD;
An AE was considered &quot;serious&quot; if it resulted in any of the following outcomes:&#xD;
Death&#xD;
Life-threatening AE&#xD;
Inpatient hospitalization or prolongation of existing hospitalization&#xD;
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions&#xD;
Congenital anomaly/birth defect.&#xD;
The Investigator assessed the relationship of each adverse event to study drug.</description>
        <time_frame>From first dose up to 28 days following the third immunization (71 days)</time_frame>
        <population>The safety population included all participants who received at least one immunization (Invaplex[AR-Detox] or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>All adverse events (AEs) were assessed for severity by the investigator according to the following scale:&#xD;
Grade 1 (Mild): Does not interfere with routine activities, minimal level of discomfort;&#xD;
Grade 2 (Moderate): Interferes with routine activities, moderate level of discomfort;&#xD;
Grade 3 (Severe): Unable to perform routine activities, significant level of discomfort;&#xD;
Grade 4 (Potentially life-threatening): Hospitalization or ER visit for potentially life-threatening event.&#xD;
An AE was considered &quot;serious&quot; if it resulted in any of the following outcomes:&#xD;
Death&#xD;
Life-threatening AE&#xD;
Inpatient hospitalization or prolongation of existing hospitalization&#xD;
Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions&#xD;
Congenital anomaly/birth defect.&#xD;
The Investigator assessed the relationship of each adverse event to study drug.</description>
          <population>The safety population included all participants who received at least one immunization (Invaplex[AR-Detox] or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="76.84" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="91.7" lower_limit="61.52" upper_limit="99.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 2 or greater AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="23.04" upper_limit="76.96"/>
                    <measurement group_id="O2" value="56.3" lower_limit="29.88" upper_limit="80.25"/>
                    <measurement group_id="O3" value="43.8" lower_limit="19.75" upper_limit="70.12"/>
                    <measurement group_id="O4" value="25.0" lower_limit="5.49" upper_limit="57.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="76.84" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="58.3" lower_limit="27.67" upper_limit="84.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 2 or greater AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="1.78" upper_limit="42.81"/>
                    <measurement group_id="O2" value="43.8" lower_limit="19.75" upper_limit="70.12"/>
                    <measurement group_id="O3" value="31.3" lower_limit="11.02" upper_limit="58.66"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="23.16"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="20.59"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="20.59"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.00" upper_limit="23.16"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="20.59"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.00" upper_limit="20.59"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 1</title>
        <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
        <time_frame>7 days after the first immunization (Days 1 to 7)</time_frame>
        <population>All participants who received the first dose (Invaplex[AR-Detox] or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 1</title>
          <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
          <population>All participants who received the first dose (Invaplex[AR-Detox] or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 2</title>
        <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
        <time_frame>7 days after the second immunization (Days 22 to 28)</time_frame>
        <population>All participants who received the second dose (Invaplex[AR-Detox] or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Events Up to 7 Days After Dose 2</title>
          <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
          <population>All participants who received the second dose (Invaplex[AR-Detox] or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Events After Dose 3</title>
        <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
        <time_frame>7 days after the third immunization (Days 43 to 49)</time_frame>
        <population>All participants who received the third dose (Invaplex[AR-Detox] or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Events After Dose 3</title>
          <description>The solicited AEs for this study included:&#xD;
Site pain&#xD;
Site tenderness&#xD;
Swelling&#xD;
Induration (determined by investigator exam)&#xD;
Site redness&#xD;
Pruritus&#xD;
Fever&#xD;
Nausea&#xD;
Vomiting&#xD;
Abdominal pain&#xD;
Diarrhea (loose stools)&#xD;
Appetite change&#xD;
Fatigue&#xD;
Headache&#xD;
Myalgias (general pain or soreness in muscles)&#xD;
Arthralgias (general pain in joints)&#xD;
Malaise</description>
          <population>All participants who received the third dose (Invaplex[AR-Detox] or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaccination site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events After Each Dose</title>
        <time_frame>Dose 1: Days 1 to 21; Dose 2: Days 22 to 42; Dose 3: Days 43 to 71</time_frame>
        <population>Participants who received each dose (Invaplex[AR-Detox] or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events After Each Dose</title>
          <population>Participants who received each dose (Invaplex[AR-Detox] or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unsolicited adverse events after first dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited adverse events after second dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited adverse events after third dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Serum Immunoglobulin A (IgA) Antibodies to Invaplex</title>
        <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Serum Immunoglobulin A (IgA) Antibodies to Invaplex</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.6" lower_limit="101.3" upper_limit="355.1"/>
                    <measurement group_id="O2" value="126.0" lower_limit="NA" upper_limit="206.8">Less than the lower limit of quantitation</measurement>
                    <measurement group_id="O3" value="141.4" lower_limit="NA" upper_limit="246.6">Less than the lower limit of quantitation</measurement>
                    <measurement group_id="O4" value="200.0" lower_limit="117.6" upper_limit="340.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3560.1" lower_limit="1077.5" upper_limit="11762.5"/>
                    <measurement group_id="O2" value="2917.5" lower_limit="1607.8" upper_limit="5294.0"/>
                    <measurement group_id="O3" value="14576.5" lower_limit="7212.2" upper_limit="29460.2"/>
                    <measurement group_id="O4" value="188.8" lower_limit="127.0" upper_limit="280.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3375.3" lower_limit="955.5" upper_limit="11922.4"/>
                    <measurement group_id="O2" value="2425.1" lower_limit="1443.2" upper_limit="4075.3"/>
                    <measurement group_id="O3" value="9451.7" lower_limit="4631.8" upper_limit="19287.4"/>
                    <measurement group_id="O4" value="165.6" lower_limit="NA" upper_limit="276.8">Less than the lower limit of quantitation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3200.0" lower_limit="975.8" upper_limit="10494.3"/>
                    <measurement group_id="O2" value="2785.8" lower_limit="1612.5" upper_limit="4812.6"/>
                    <measurement group_id="O3" value="11033.3" lower_limit="5649.8" upper_limit="21546.2"/>
                    <measurement group_id="O4" value="149.8" lower_limit="NA" upper_limit="241.5">Less than the lower limit of quantitation</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4271.5" lower_limit="1293.7" upper_limit="14103.6"/>
                    <measurement group_id="O2" value="3200.0" lower_limit="1729.1" upper_limit="5922.1"/>
                    <measurement group_id="O3" value="10307.1" lower_limit="5419.5" upper_limit="19602.9"/>
                    <measurement group_id="O4" value="178.2" lower_limit="109.1" upper_limit="291.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4031.7" lower_limit="1063.9" upper_limit="15279.1"/>
                    <measurement group_id="O2" value="2211.1" lower_limit="1158.1" upper_limit="4221.3"/>
                    <measurement group_id="O3" value="9451.7" lower_limit="4883.7" upper_limit="18292.3"/>
                    <measurement group_id="O4" value="211.9" lower_limit="126.9" upper_limit="353.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.504</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 22</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Serum Immunoglobulin G (IgG) Antibodies to Invaplex</title>
        <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Serum Immunoglobulin G (IgG) Antibodies to Invaplex</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1516.9" lower_limit="850.2" upper_limit="2706.4"/>
                    <measurement group_id="O2" value="1269.9" lower_limit="592.0" upper_limit="2723.9"/>
                    <measurement group_id="O3" value="2166.8" lower_limit="1308.9" upper_limit="3587.0"/>
                    <measurement group_id="O4" value="1695.1" lower_limit="830.0" upper_limit="3461.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15020.3" lower_limit="4474.5" upper_limit="50421.6"/>
                    <measurement group_id="O2" value="22286.1" lower_limit="11426.7" upper_limit="43465.7"/>
                    <measurement group_id="O3" value="75613.5" lower_limit="41386.6" upper_limit="138146.2"/>
                    <measurement group_id="O4" value="1795.9" lower_limit="916.5" upper_limit="3519.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25600.0" lower_limit="8027.0" upper_limit="81644.6"/>
                    <measurement group_id="O2" value="29406.7" lower_limit="15572.4" upper_limit="55531.0"/>
                    <measurement group_id="O3" value="106933.6" lower_limit="65186.0" upper_limit="175418.1"/>
                    <measurement group_id="O4" value="1704.1" lower_limit="696.6" upper_limit="4168.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27122.3" lower_limit="8727.4" upper_limit="84288.0"/>
                    <measurement group_id="O2" value="37050.1" lower_limit="20418.3" upper_limit="67229.4"/>
                    <measurement group_id="O3" value="113058.8" lower_limit="70861.9" upper_limit="180383.0"/>
                    <measurement group_id="O4" value="1795.9" lower_limit="996.7" upper_limit="3236.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34171.9" lower_limit="11722.7" upper_limit="99611.8"/>
                    <measurement group_id="O2" value="44572.2" lower_limit="22853.4" upper_limit="86931.5"/>
                    <measurement group_id="O3" value="116612.0" lower_limit="79218.2" upper_limit="171656.8"/>
                    <measurement group_id="O4" value="2015.9" lower_limit="1135.8" upper_limit="3577.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36203.9" lower_limit="13769.6" upper_limit="95189.5"/>
                    <measurement group_id="O2" value="42559.4" lower_limit="23621.8" upper_limit="76679.4"/>
                    <measurement group_id="O3" value="106933.6" lower_limit="65186.0" upper_limit="175418.1"/>
                    <measurement group_id="O4" value="1425.4" lower_limit="747.1" upper_limit="2719.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 22</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Immunoglobulin A Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant (ALS)</title>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Immunoglobulin A Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant (ALS)</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.0" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as there was no variation among participants in this arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" lower_limit="36.1" upper_limit="539.9"/>
                    <measurement group_id="O2" value="115.2" lower_limit="21.6" upper_limit="614.4"/>
                    <measurement group_id="O3" value="275.5" lower_limit="62.1" upper_limit="1222.3"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.9" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="5.8" upper_limit="64.7"/>
                    <measurement group_id="O2" value="11.0" lower_limit="4.0" upper_limit="30.7"/>
                    <measurement group_id="O3" value="8.8" lower_limit="3.8" upper_limit="20.6"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.8" upper_limit="13.2"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.8" upper_limit="8.7"/>
                    <measurement group_id="O3" value="4.4" lower_limit="2.2" upper_limit="9.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as there was no variation among participants in this arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.601</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.628</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Immunoglobulin G Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant</title>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Immunoglobulin G Antibodies to Invaplex in α4β7+ Antibody in Lymphocyte Supernatant</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O3" value="1.1" lower_limit="1.0" upper_limit="1.3"/>
                    <measurement group_id="O4" value="1.3" lower_limit="0.7" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.6" lower_limit="76.6" upper_limit="1259.2"/>
                    <measurement group_id="O2" value="220.1" lower_limit="38.3" upper_limit="1266.3"/>
                    <measurement group_id="O3" value="806.7" lower_limit="192.9" upper_limit="3373.5"/>
                    <measurement group_id="O4" value="1.5" lower_limit="0.9" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" lower_limit="7.1" upper_limit="78.3"/>
                    <measurement group_id="O2" value="56.1" lower_limit="14.5" upper_limit="217.0"/>
                    <measurement group_id="O3" value="80.8" lower_limit="31.8" upper_limit="205.0"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" lower_limit="5.0" upper_limit="38.2"/>
                    <measurement group_id="O2" value="71.2" lower_limit="20.5" upper_limit="246.5"/>
                    <measurement group_id="O3" value="65.4" lower_limit="17.8" upper_limit="240.2"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.762</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.335</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMT at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 4-fold Increase in Serum IgA Antibodies From Baseline</title>
        <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
        <time_frame>Days 1 (Baseline), 22 43, 50, 57 and 71</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 4-fold Increase in Serum IgA Antibodies From Baseline</title>
          <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="63.97" upper_limit="99.81"/>
                    <measurement group_id="O2" value="86.7" lower_limit="59.54" upper_limit="98.34"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="75.29" upper_limit="100.00"/>
                    <measurement group_id="O2" value="86.7" lower_limit="59.54" upper_limit="98.34"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.05" upper_limit="99.83"/>
                    <measurement group_id="O3" value="92.9" lower_limit="66.13" upper_limit="99.82"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.05" upper_limit="99.83"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.52" upper_limit="99.79"/>
                    <measurement group_id="O2" value="86.7" lower_limit="59.54" upper_limit="98.34"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 22.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.828</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.629</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.825</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 4-fold Increase in Serum IgG Antibodies From Baseline</title>
        <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
        <time_frame>Days 1 (Baseline), 22 43, 50, 57 and 71</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 4-fold Increase in Serum IgG Antibodies From Baseline</title>
          <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="38.57" upper_limit="90.91"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="54.55" upper_limit="98.08"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="61.52" upper_limit="99.79"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100." lower_limit="76.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.20" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value=".0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="73.54" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="78.20" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.0" lower_limit="79.41" upper_limit="100.00"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 22.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.293</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail test of the difference between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 4-fold Increase in ALS IgA From Baseline</title>
        <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 4-fold Increase in ALS IgA From Baseline</title>
          <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="63.97" upper_limit="99.81"/>
                    <measurement group_id="O2" value="86.7" lower_limit="59.54" upper_limit="98.34"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="46.19" upper_limit="94.96"/>
                    <measurement group_id="O2" value="73.3" lower_limit="44.90" upper_limit="92.21"/>
                    <measurement group_id="O3" value="66.7" lower_limit="38.38" upper_limit="88.18"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="21.09" upper_limit="78.91"/>
                    <measurement group_id="O2" value="40.0" lower_limit="16.34" upper_limit="67.71"/>
                    <measurement group_id="O3" value="42.9" lower_limit="17.66" upper_limit="71.14"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.828</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.913</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.924</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥ 4-fold Increase in ALS IgG From Baseline</title>
        <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥ 4-fold Increase in ALS IgG From Baseline</title>
          <description>Seroconversion was defined as ≥ 4-fold increase in antibody titer from Baseline.</description>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="75.29" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.05" upper_limit="99.83"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.77" upper_limit="99.84"/>
                    <measurement group_id="O4" value="8.3" lower_limit="0.21" upper_limit="38.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="46.19" upper_limit="94.96"/>
                    <measurement group_id="O2" value="93.3" lower_limit="68.05" upper_limit="99.83"/>
                    <measurement group_id="O3" value="93.3" lower_limit="68.05" upper_limit="99.83"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.59" upper_limit="97.91"/>
                    <measurement group_id="O2" value="86.7" lower_limit="59.54" upper_limit="98.34"/>
                    <measurement group_id="O3" value="92.9" lower_limit="66.13" upper_limit="99.82"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.00" upper_limit="26.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.412</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher's exact 2-tail tests of differences between the 3 Invaplex[AR-Detox] dose groups in seroconversion rates at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.847</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold-rise (GMFR) in Serum IgA From Baseline</title>
        <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold-rise (GMFR) in Serum IgA From Baseline</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>fold-rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="7.3" upper_limit="48.0"/>
                    <measurement group_id="O2" value="23.2" lower_limit="10.5" upper_limit="51.2"/>
                    <measurement group_id="O3" value="103.1" lower_limit="46.0" upper_limit="230.8"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="7.3" upper_limit="43.2"/>
                    <measurement group_id="O2" value="19.2" lower_limit="9.3" upper_limit="40.0"/>
                    <measurement group_id="O3" value="66.8" lower_limit="30.3" upper_limit="147.5"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.6" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="7.5" upper_limit="33.9"/>
                    <measurement group_id="O2" value="22.1" lower_limit="11.0" upper_limit="44.2"/>
                    <measurement group_id="O3" value="74.2" lower_limit="34.3" upper_limit="160.7"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.6" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="8.8" upper_limit="52.0"/>
                    <measurement group_id="O2" value="25.4" lower_limit="11.8" upper_limit="54.5"/>
                    <measurement group_id="O3" value="72.9" lower_limit="34.3" upper_limit="154.8"/>
                    <measurement group_id="O4" value="0.9" lower_limit="0.8" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="8.1" upper_limit="49.9"/>
                    <measurement group_id="O2" value="17.5" lower_limit="7.8" upper_limit="39.3"/>
                    <measurement group_id="O3" value="66.8" lower_limit="30.3" upper_limit="147.5"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.8" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 22</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold-rise in Serum IgG From Baseline</title>
        <time_frame>Days 1 (Baseline), 22, 43, 50, 57 and 71.</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold-rise in Serum IgG From Baseline</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>fold-rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 22 (pre-dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="3.8" upper_limit="25.8"/>
                    <measurement group_id="O2" value="17.5" lower_limit="10.9" upper_limit="28.3"/>
                    <measurement group_id="O3" value="34.9" lower_limit="20.4" upper_limit="59.7"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.8" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (pre-dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="6.8" upper_limit="42.0"/>
                    <measurement group_id="O2" value="23.2" lower_limit="11.7" upper_limit="45.6"/>
                    <measurement group_id="O3" value="49.4" lower_limit="27.5" upper_limit="88.7"/>
                    <measurement group_id="O4" value="1.0" lower_limit="0.7" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="7.0" upper_limit="41.3"/>
                    <measurement group_id="O2" value="29.2" lower_limit="16.4" upper_limit="52.0"/>
                    <measurement group_id="O3" value="45.3" lower_limit="23.8" upper_limit="86.0"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.8" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (14 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="9.7" upper_limit="46.8"/>
                    <measurement group_id="O2" value="35.1" lower_limit="18.7" upper_limit="65.9"/>
                    <measurement group_id="O3" value="53.8" lower_limit="30.6" upper_limit="94.6"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.8" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (28 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="11.1" upper_limit="46.3"/>
                    <measurement group_id="O2" value="33.5" lower_limit="16.8" upper_limit="66.7"/>
                    <measurement group_id="O3" value="49.4" lower_limit="27.1" upper_limit="90.0"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.6" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 22</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 43</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.146</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 57</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 71</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold-rise in ALS IgA From Baseline</title>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold-rise in ALS IgA From Baseline</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest</population>
          <units>fold-rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.3" lower_limit="35.8" upper_limit="489.4"/>
                    <measurement group_id="O2" value="87.3" lower_limit="18.6" upper_limit="410.2"/>
                    <measurement group_id="O3" value="241.9" lower_limit="53.4" upper_limit="1095.1"/>
                    <measurement group_id="O4" value="1.2" lower_limit="0.9" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="5.3" upper_limit="63.7"/>
                    <measurement group_id="O2" value="8.4" lower_limit="3.4" upper_limit="20.5"/>
                    <measurement group_id="O3" value="7.7" lower_limit="3.3" upper_limit="18.0"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="1.6" upper_limit="12.8"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.5" upper_limit="6.0"/>
                    <measurement group_id="O3" value="3.8" lower_limit="1.8" upper_limit="8.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="NA" upper_limit="NA">Confidence interval could not be calculated as there was no variation among participants in this arm at this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold-rise in ALS IgG From Baseline</title>
        <time_frame>Days 1 (Baseline), 8, 29, and 50</time_frame>
        <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>Invaplex[AR-Detox] 2.5 μg</title>
            <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O2">
            <title>Invaplex[AR-Detox] 10 μg</title>
            <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O3">
            <title>Invaplex[AR-Detox] 25 μg</title>
            <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold-rise in ALS IgG From Baseline</title>
          <population>The immunogenicity population includes all participants who received at least two vaccinations, who had baseline and post-vaccination data for the immunogenicity variable of interest.</population>
          <units>fold-rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (7 days after dose 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.9" lower_limit="62.0" upper_limit="1015.4"/>
                    <measurement group_id="O2" value="200.7" lower_limit="36.5" upper_limit="1103.6"/>
                    <measurement group_id="O3" value="708.3" lower_limit="163.3" upper_limit="3072.4"/>
                    <measurement group_id="O4" value="1.1" lower_limit="0.6" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (7 days after dose 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="5.6" upper_limit="64.7"/>
                    <measurement group_id="O2" value="51.2" lower_limit="13.8" upper_limit="190.1"/>
                    <measurement group_id="O3" value="70.3" lower_limit="28.2" upper_limit="175.6"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.4" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (7 days after dose 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="4.6" upper_limit="33.2"/>
                    <measurement group_id="O2" value="64.9" lower_limit="19.1" upper_limit="220.1"/>
                    <measurement group_id="O3" value="59.2" lower_limit="15.7" upper_limit="223.6"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.5" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis test of any difference between the 3 active dose groups in GMFR at Day 50</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose up to 28 days following the third immunization (71 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Invaplex[AR-Detox] 2.5 μg</title>
          <description>Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="E2">
          <title>Invaplex[AR-Detox] 10 μg</title>
          <description>Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="E3">
          <title>Invaplex[AR-Detox] 25 μg</title>
          <description>Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site induration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rahsan Erdem</name_or_title>
      <organization>PATH</organization>
      <phone>+1 202 540 4546</phone>
      <email>rerdem@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

